Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://link.springer.com/article/10.1007/s10719-017-9798-z, but it redirected us to https://link.springer.com/article/10.1007/s10719-017-9798-z. The analysis below is for the second page.

Title[redir]:
Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans | Glycoconjugate Journal
Description:
Dental caries remains a major health issue and the Gram-positive bacterium Streptococcus mutans is considered as the major pathogen causing caries. More recently, S. mutans has been recognised as a cause of endocarditis, ulcerative colitis and fatty acid liver disease along with the likelihood of increased cerebral hemorrhage following a stroke if S. mutans is present systemically. We initiated this study to examine the vaccine candidacy of the serotype specific polysaccharides elaborated by S. mutans. We have confirmed the carbohydrate structures for the serotype specific rhamnan containing polysaccharides from serotypes c, f and k. We have prepared glycoconjugate vaccines using the rhamnan containing polymers from serotypes f and k and immunised mice and rabbits. We consistently obtained a robust immune response to the glycoconjugates with cross-reactivity consistent with the structural similarities of the polymers from the different serotypes. We developed an opsonophagocytic assay which illustrated the ability of the post-immune sera to facilitate opsonophagocytic killing of the homologous and heterologous serotypes at titers consistent with the structural homologies. We conclude that glycoconjugates of the rhamnan polymers of S. mutans are a potential vaccine candidate to target dental caries and other sequelae following the escape of S. mutans from the oral cavity.

Matching Content Categories {๐Ÿ“š}

  • Science
  • Education
  • Politics

Content Management System {๐Ÿ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of doi.org audience?

๐Ÿ™๏ธ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {๐Ÿ’ธ}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {๐Ÿ”}

article, mutans, pubmed, streptococcus, google, scholar, cas, oral, serotype, rhamnan, caries, vaccine, dental, central, polysaccharide, disease, health, privacy, cookies, content, journal, research, specific, structural, access, protein, nakano, strain, publish, search, glycoconjugates, yang, cox, endocarditis, serotypes, binding, immunol, ooshima, streptococci, infect, immun, res, michalek, mcghee, units, data, information, log, glycoconjugate, candidacy,

Topics {โœ’๏ธ}

month download article/chapter prepared glycoconjugate vaccines glycosyltransferase-mediated sweet modification streptococcus mutans-derived glucosyltransferases major health issue collagen binding protein enzyme-linked immunosorbent assay serotype specific rhamnan target dental caries related subjects streptococcus mutans serotype full article pdf privacy choices/manage cookies potential vaccine candidate elsevier science publishing streptococcus mutans omz175 national research council serotype carbohydrate antigens human participants performed recombinant form public health imperative dental caries infective endocarditis plant-derived antibody rhamnan repeating units effective oral health prevent disease caused inflammatory bowel disease article st european economic area increased cerebral hemorrhage robust immune response post-immune sera young galician population high street mouthwashes extracellular matrix formation gas liquid chromatography 1hโ€“nmr spectrum journal finder publish conditions privacy policy induce protective immunity cross-reactivity consistent facilitate opsonophagocytic killing polysaccharide antigen annie aubryย &ย andrew viridans group streptococci streptococcus mutans vivo protective effects accepting optional cookies check access

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans
         description:Dental caries remains a major health issue and the Gram-positive bacterium Streptococcus mutans is considered as the major pathogen causing caries. More recently, S. mutans has been recognised as a cause of endocarditis, ulcerative colitis and fatty acid liver disease along with the likelihood of increased cerebral hemorrhage following a stroke if S. mutans is present systemically. We initiated this study to examine the vaccine candidacy of the serotype specific polysaccharides elaborated by S. mutans. We have confirmed the carbohydrate structures for the serotype specific rhamnan containing polysaccharides from serotypes c, f and k. We have prepared glycoconjugate vaccines using the rhamnan containing polymers from serotypes f and k and immunised mice and rabbits. We consistently obtained a robust immune response to the glycoconjugates with cross-reactivity consistent with the structural similarities of the polymers from the different serotypes. We developed an opsonophagocytic assay which illustrated the ability of the post-immune sera to facilitate opsonophagocytic killing of the homologous and heterologous serotypes at titers consistent with the structural homologies. We conclude that glycoconjugates of the rhamnan polymers of S. mutans are a potential vaccine candidate to target dental caries and other sequelae following the escape of S. mutans from the oral cavity.
         datePublished:2017-10-02T00:00:00Z
         dateModified:2017-10-02T00:00:00Z
         pageStart:53
         pageEnd:64
         sameAs:https://doi.org/10.1007/s10719-017-9798-z
         keywords:
             Streptococcus Mutans
            Conjugate vaccine
            Serotype polysaccharide
            Rhamnan
            Biochemistry
            general
            Pathology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig5a_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig5b_HTML.gif
         isPartOf:
            name:Glycoconjugate Journal
            issn:
               1573-4986
               0282-0080
            volumeNumber:35
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Frank St. Michael
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Qingling Yang
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chantelle Cairns
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Evgeny Vinogradov
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Perry Fleming
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alexander C. Hayes
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Annie Aubry
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrew D. Cox
               url:http://orcid.org/0000-0002-8397-9271
               affiliation:
                     name:National Research Council
                     address:
                        name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Investigating the candidacy of the serotype specific rhamnan polysaccharide based glycoconjugates to prevent disease caused by the dental pathogen Streptococcus mutans
      description:Dental caries remains a major health issue and the Gram-positive bacterium Streptococcus mutans is considered as the major pathogen causing caries. More recently, S. mutans has been recognised as a cause of endocarditis, ulcerative colitis and fatty acid liver disease along with the likelihood of increased cerebral hemorrhage following a stroke if S. mutans is present systemically. We initiated this study to examine the vaccine candidacy of the serotype specific polysaccharides elaborated by S. mutans. We have confirmed the carbohydrate structures for the serotype specific rhamnan containing polysaccharides from serotypes c, f and k. We have prepared glycoconjugate vaccines using the rhamnan containing polymers from serotypes f and k and immunised mice and rabbits. We consistently obtained a robust immune response to the glycoconjugates with cross-reactivity consistent with the structural similarities of the polymers from the different serotypes. We developed an opsonophagocytic assay which illustrated the ability of the post-immune sera to facilitate opsonophagocytic killing of the homologous and heterologous serotypes at titers consistent with the structural homologies. We conclude that glycoconjugates of the rhamnan polymers of S. mutans are a potential vaccine candidate to target dental caries and other sequelae following the escape of S. mutans from the oral cavity.
      datePublished:2017-10-02T00:00:00Z
      dateModified:2017-10-02T00:00:00Z
      pageStart:53
      pageEnd:64
      sameAs:https://doi.org/10.1007/s10719-017-9798-z
      keywords:
          Streptococcus Mutans
         Conjugate vaccine
         Serotype polysaccharide
         Rhamnan
         Biochemistry
         general
         Pathology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig5a_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10719-017-9798-z/MediaObjects/10719_2017_9798_Fig5b_HTML.gif
      isPartOf:
         name:Glycoconjugate Journal
         issn:
            1573-4986
            0282-0080
         volumeNumber:35
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Frank St. Michael
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Qingling Yang
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chantelle Cairns
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Evgeny Vinogradov
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Perry Fleming
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alexander C. Hayes
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Annie Aubry
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrew D. Cox
            url:http://orcid.org/0000-0002-8397-9271
            affiliation:
                  name:National Research Council
                  address:
                     name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Glycoconjugate Journal
      issn:
         1573-4986
         0282-0080
      volumeNumber:35
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
      name:National Research Council
      address:
         name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Frank St. Michael
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Qingling Yang
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Chantelle Cairns
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Evgeny Vinogradov
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Perry Fleming
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Alexander C. Hayes
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Annie Aubry
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:Andrew D. Cox
      url:http://orcid.org/0000-0002-8397-9271
      affiliation:
            name:National Research Council
            address:
               name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
      name:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(167)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

Emails and Hosting {โœ‰๏ธ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {๐Ÿ“ฆ}

  • Crossref

5.08s.